Actively Recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Led by Imperial College London · Updated on 2026-03-24
1005
Participants Needed
1
Research Sites
176 weeks
Total Duration
On this page
Sponsors
I
Imperial College London
Lead Sponsor
P
Pancreatic Cancer UK
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all. Jaundice, weight loss and pain are 'red flag' symptoms of pancreatic cancer that are linked to incurable disease. At the moment only patients with 'red flag' symptoms are urgently referred for diagnostic testing to find out if they have the cancer. As a result, late diagnosis is a common feature of pancreatic cancer. This leads to limited treatment options being available to patients by the time they are diagnosed, and ultimately results in poor survival rates. There is a clear need to improve earlier detection of pancreatic cancer so that patients with pancreatic cancer can be identified earlier and faster, enabling them to start treatment more quickly. The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that may be altered by pancreatic cancers. For patients with non-specific symptoms, this test would help general practitioners (GPs) to identify those patients that may indeed have an underlying pancreatic cancer, who would benefit from referral for specialised pancreatic cancer tests.
CONDITIONS
Official Title
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female adults aged 18 years or older
- For VAPOR 1: patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC), new-onset diabetes mellitus, chronic pancreatitis, or non-specific gastrointestinal symptoms with a normal pancreas on imaging
- For VAPOR Bioresource: patients undergoing pancreatic surgery for histologically confirmed PDAC or benign pancreatic conditions such as intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, or chronic pancreatitis
- Patients undergoing surgery for suspected PDAC may be included if PDAC is confirmed after surgery
You will not qualify if you...
- Patients who have already received chemotherapy, radiotherapy, or surgery for PDAC
- History of another cancer within the past five years
- Previous upper gastrointestinal surgery
- Inability to provide a breath sample
- Pregnant women
- Unable to provide informed written consent
- For VAPOR 1: active infection or use of immunosuppressive medications or antibiotics within the past eight weeks
- For VAPOR Bioresource: use of immunosuppressive medications within the past eight weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Imperial College Healthcare NHS Trust
London, United Kingdom
Actively Recruiting
Research Team
M
Miss Caoimhe M Walsh, MBBS, MRCS
CONTACT
E
Emma Austin
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here